Recent Updates — COSM
Cosmos Health Inc. issued a press release and CEO letter announcing preliminary expectations for its fourth fiscal quarter ending December 31, 2026. The company expects U.S. revenue to reach approximately $15 million, driven by subscription growth that increased 42% in five days to 8,940 active subscriptions. This growth supports an expected gross profit of $10.5 million at a 70% margin. Additionally, the CEO reaffirmed full-year 2026 revenue guidance to surpass $90 million and provided long-term targets for 2029. Cosmos Health Inc. operates as a diversified, vertically integrated global healthcare group involved in pharmaceutical manufacturing, distribution, proprietary brands, and direct-to-consumer e-commerce.
Cosmos Health Inc. announced preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026, representing a 19% increase from $45.6 million in the same period of 2025. Third-quarter revenue reached a record $17.4 million, up 40% year over year. The company reaffirmed its full-year 2026 revenue outlook to surpass $90 million. Cosmos Health operates as a diversified, vertically integrated global healthcare group involved in contract manufacturing, pharmaceutical distribution, and proprietary brands.
Cosmos Health Inc. reported second quarter and first half financial results for the period ended June 30, 2026. Revenue reached $18.99 million in Q2, a 28.8% increase year-over-year, bringing first-half revenue to $36.91 million, up 29.7%. Adjusted gross profit rose 58.4% to $1.84 million in Q2, with adjusted gross margin expanding 165 basis points to 9.54%. The company reduced total liabilities by 13.3% ($6.27 million) and increased stockholders' equity by 12.2% to $20.67 million. Additionally, Cosmos Health announced a share repurchase program authorized for up to $5.0 million, under which it purchased approximately $1.11 million worth of shares through the end of Q3.
At the 2026 Annual Meeting of Stockholders held on July 15, 2026, Cosmos Health Inc. stockholders approved the designation and issuance of 100,000 shares of Series B Preferred Stock. The meeting also resulted in the election of six directors, including Grigorios Siokas and Theodoros C. Karkantzos, and the ratification of its independent registered public accounting firm. Cosmos Health Inc. operates in the healthcare sector and provides various health-related products and services.
On June 30, 2026, the Board of Directors of Cosmos Health Inc. authorized a share repurchase program for up to $5 million of the company's outstanding common stock. The program is scheduled to run for six months, ending on December 31, 2026, and may involve open market purchases, private transactions, or block purchases. The company also authorized the use of Rule 10b5-1 trading plans to facilitate these repurchases. Cosmos Health Inc. is a healthcare company.